Industries de la santé

Pluristem Receives Approval to Commence a Phase I/II Study for Muscle Regeneration in Germany

Imprimer PDF

Écrit par Pluristem | 07 Août 2012

Clinical trial to demonstrate safety and efficacy of PLX cells for regeneration of injured gluteal muscle following total hip replacement

HAIFA, ISRAEL, August 7, 2012 -- Pluristem Therapeutics, Inc. (NASDAQCM:PSTI; TASE: PLTR), a leading developer of placenta-based cell therapies, today announced it has received approval from the Paul-Ehrlich-Institute (PEI), the medical regulatory body...

Lire la suite... Ajouter un commentaire

Fragile X and Down syndromes share signalling pathway for intellectual disability

Imprimer PDF

Écrit par Enbo Journal | 06 Août 2012

HEIDELBERG, 6 August 2012 – Intellectual disability due to Fragile X and Down syndromes involves similar molecular pathways report researchers in The EMBO Journal. The two disorders share disturbances in the molecular events that regulate the way nerve cells develop dendritic spines, the small extensions found on the surface of nerve cells that are crucial for communication in the...

Lire la suite... Ajouter un commentaire

Intelligent Design: IntelligentMDx’s New Herpes Diagnostic Test Receives EU Approval

Imprimer PDF

Écrit par GlobalData | 01 Août 2012

LONDON, UK (GlobalData), 26 July 2012 - IntelligentMDx received EU approval of their new diagnostic test, IMDx HSV-1/2, which detects the presence of HSV nucleic acids and differentiates between Herpes simplex virus 1 and 2 (HSV-1 and HSV-2). The IMDx HSV-1/2 is designed to complement the use of the Abbott m2000 RealTime system, manufactured by Abbott Molecular, a subsidiary of Abbott...

Lire la suite... Ajouter un commentaire

Pluristem Partners with CPC Clinical Research for Peripheral Artery Disease Study

Imprimer PDF

Écrit par Pluristem | 23 Juillet 2012

HAIFA, ISRAEL, July 18, 2012 -- Pluristem Therapeutics, Inc. (NASDAQ:PSTI; TASE: PLTR), today announced that in anticipation of initiating a Phase II study using PLX-PAD cells for the treatment of Intermittent Claudication (IC), the company has recently entered into a collaborative agreement with CPC Clinical Research (CPC) for services related to enrolling and sustaining clinical sites...

Lire la suite... Ajouter un commentaire

Another Biotech Gets Absorbed: GSK Acquires HGS in a $3 Billion Deal

Imprimer PDF

Écrit par Globaldata | 19 Juillet 2012

LONDON, UK (GlobalData), 18 July 2012 - GlaxoSmithKline (GSK), the British pharmaceutical giant, acquired Human Genome Sciences (HGS) on Monday, July 16, 2012 for $14.25/share. On an equity basis this deal was worth about $3.6 billion; however, the final deal size was approximately $3 billion net of cash and debt. GSK paid a premium of 99% from when it offered its initial private...

Lire la suite... Ajouter un commentaire

Biobetters: The Big Draw in the Pharma Market

Imprimer PDF

Écrit par GBI | 16 Juillet 2012

NEW YORK (GBI Research), 13 July 2012 - Biobetters, drugs that have been improved since their initial incarnations, are demonstrating fantastic growth and leaving their originators well behind, states new research by pharmaceutical business specialists GBI Research.

The new report* explains how the more advanced drugs are far outstripping their biologic predecessors in terms of sales and...

Lire la suite... Ajouter un commentaire

New wet mill dramatically improves api milling capabilities

Imprimer PDF

Écrit par Quadro | 13 Juillet 2012

The Quadro Ytron® HV-Emulsifier Group Seri

Waterloo, Canada, July 11, 2012 - Size Reduction or Milling of APIs (Active Pharmaceutical Ingredients) is a key step in the drug development process. When milling an API, the developer requires a tight particle size distribution that ensures consistent drug substance and drug product quality. Traditionally, dry milling technologies such as...

Lire la suite... Ajouter un commentaire

Vexim poursuit son développement en Europe et s'implante en Italie

Imprimer PDF

Écrit par Vexim | 06 Juillet 2012

Création de Vexim Italie, deuxième filiale de Vexim après l'Allemagne


Toulouse, le 6 juillet 2012 - Vexim (FR0011072602 ALVXM), société de dispositifs médicaux  spécialisée dans le traitement mini-invasif des fractures vertébrales, annonce la création de sa filiale italienne à Milan. Disposant déjà d'une forte notoriété en Italie, la filiale va permettre à Vexim...

Lire la suite... Ajouter un commentaire

Despite Lofty Goals, Generating Antibiotic Incentives Now (GAIN) Act Falls Short

Imprimer PDF

Écrit par GlobalData | 03 Juillet 2012

LONDON, UK (GlobalData), 3 July 2012 - While the world focused on the fate of the Affordable Care Act, another important piece of healthcare legislation worked its way through Congress, the Prescription Drug User Fee Act (PDUFA) V. First introduced in 1992, PDUFA authorizes the FDA to collect fees from companies seeking approval of new drugs. The FDA uses these funds to hasten the drug...

Lire la suite... Commentaires (1)

Plus d'articles...

Information

Annuaires

Vitrines Sociétés

Voir toutes les vitrines